# Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes

> **NCT05248776** · PHASE2 · UNKNOWN · sponsor: **Celon Pharma SA** · enrollment: 80 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** CPL207280
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05248776
- **Lead sponsor:** Celon Pharma SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-21
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05248776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05248776, "Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05248776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*